1. Home
  2. PRG vs MIRM Comparison

PRG vs MIRM Comparison

Compare PRG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRG
  • MIRM
  • Stock Information
  • Founded
  • PRG 2020
  • MIRM 2018
  • Country
  • PRG United States
  • MIRM United States
  • Employees
  • PRG N/A
  • MIRM N/A
  • Industry
  • PRG Diversified Commercial Services
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRG Consumer Discretionary
  • MIRM Health Care
  • Exchange
  • PRG Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • PRG 1.1B
  • MIRM 2.5B
  • IPO Year
  • PRG N/A
  • MIRM 2019
  • Fundamental
  • Price
  • PRG $30.18
  • MIRM $52.66
  • Analyst Decision
  • PRG Strong Buy
  • MIRM Strong Buy
  • Analyst Count
  • PRG 5
  • MIRM 9
  • Target Price
  • PRG $41.80
  • MIRM $66.22
  • AVG Volume (30 Days)
  • PRG 385.5K
  • MIRM 465.4K
  • Earning Date
  • PRG 07-23-2025
  • MIRM 08-06-2025
  • Dividend Yield
  • PRG 1.70%
  • MIRM N/A
  • EPS Growth
  • PRG 99.08
  • MIRM N/A
  • EPS
  • PRG 4.90
  • MIRM N/A
  • Revenue
  • PRG $2,505,714,000.00
  • MIRM $379,251,000.00
  • Revenue This Year
  • PRG $1.36
  • MIRM $35.83
  • Revenue Next Year
  • PRG $4.29
  • MIRM $16.83
  • P/E Ratio
  • PRG $6.11
  • MIRM N/A
  • Revenue Growth
  • PRG 4.62
  • MIRM 69.31
  • 52 Week Low
  • PRG $23.50
  • MIRM $36.17
  • 52 Week High
  • PRG $50.28
  • MIRM $54.23
  • Technical
  • Relative Strength Index (RSI)
  • PRG 56.16
  • MIRM 64.66
  • Support Level
  • PRG $29.85
  • MIRM $49.22
  • Resistance Level
  • PRG $30.83
  • MIRM $53.86
  • Average True Range (ATR)
  • PRG 0.79
  • MIRM 1.57
  • MACD
  • PRG 0.06
  • MIRM 0.08
  • Stochastic Oscillator
  • PRG 75.82
  • MIRM 79.63

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: